Investors focused on the Medical space have likely heard of Advaxis (ADXS), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Advaxis is a member of our Medical group, which includes 850 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ADXS is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ADXS's full-year earnings has moved 74.47% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ADXS has returned 35.15% so far this year. Meanwhile, stocks in the Medical group have gained about 10.03% on average. This shows that Advaxis is outperforming its peers so far this year.
Looking more specifically, ADXS belongs to the Medical - Biomedical and Genetics industry, a group that includes 355 individual stocks and currently sits at #86 in the Zacks Industry Rank. This group has gained an average of 16.29% so far this year, so ADXS is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to ADXS as it looks to continue its solid performance.
Advaxis, Inc. (ADXS): Free Stock Analysis Report
Original post
Zacks Investment Research